🇫🇷🇨🇦🇺🇸 Associate Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies
I’m pleased to share Mayo Clinic has announced a strategic collaboration with @Microsoft to develop and deploy a frontier AI model designed specifically for healthcare. Read more: https://t.co/I6RGCtR8MF
Brilliant discussant slide from @CalaisJeremie putting into context the results from AcTION and CONV01-alpha with PSMAddition and VISION
@urotoday#ASCO26
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial (Study Protocol)
https://t.co/itjQDJ7ckH
BRIO is a prospective randomized trial evaluating whether immediate salvage radiotherapy (SRT) ☢️ improves outcomes versus observation with delayed image-guided treatment in men with biochemical recurrence after radical prostatectomy who have negative mpMRI and PSMA-PET/CT imaging.
The study will enroll 312 patients with PSA 🧪 0.2–1.5 ng/mL and assess distant recurrence-free survival, quality of life, adverse effects, and biomarker development to clarify optimal management of imaging-negative recurrent #ProstateCancer after surgery overall
@DrStish@JakeOrmeMDPhD@vidit_sharma_@JackAndrewsMD@flscientist@OncoAlert 🚨
@Silke_Gillessen@AOmlin@weoncologists
What a day it has been!!!
@AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment?
Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!
Our talented collaborator Dr. Ishwor Thapa, bioinformatician and data scientist at UNO, presenting an important comparative analysis of total and small RNAseq for EV biomarker discovery.
#ISEV2026
We were honored to host Dr. Michael Blute today for a lecture on surgical management of tumor thrombus in RCC.
Key insights on operative strategy and multidisciplinary care underscored opportunities to improve outcomes in complex cases.
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: https://t.co/bzVbmJXHMD